Hepatitis C - Three Rivers Pharmaceuticals Announces FDA Final Approval of Ribasphere(R) (ribavirin, USP) Tablets 600mg, 400

Three Rivers Pharmaceuticals Announces FDA Final Approval of Ribasphere(R) (ribavirin, USP) Tablets 600mg, 400
Drug News Wire - alfa-2a for the treatment of Hepatitis C ('HCV'). Three Rivers Pharmaceuticals and PAR Pharmaceuticals will be shipping advance in the treatment of HCV since the launch of Pegasys(R

2.2% Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+
National AIDS Treatment Advocacy Project - Liver Cancer developed Among Sexual among HCV+ Conference Reports for NATAP AASLD American Association Cancer developed Among Sexual among HCV+ Reported by Jules Levin from AASLD

PR Newswire: Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monothera
Belga Direct Press Releases - HCV genotype 1 is the most commonform of the virus worldwide and is considered the most difficult to treatsuccessfully. patients chronically infected withhepatitis C virus (HCV) genotype 1 who were nonresponders to

Pegasys shows encouraging interim results for HCV patients in whom PegIntron therapy failed
InPharm.com - The study looked at early markers of the efficacy and safety of different regimens of Pegasys+Copegus combination therapy in 950 patients with HCV in whom previous treatment with PegIntron+Rebetol failed to generate a sustained virologic response. viral levels in hepatitis C (HCV) patients for whom treatment with PegIntron

FDA gives Fast Track status to Vertex's Hepatitis C treatment
Mass High Tech - to VX-950, an investigational oral hepatitis C virus (HCV) treatment being developed by Vertex Pharmaceuticals Inc and dramatic reduction in HCV RNA in HCV patients when VX-950

MULTICENTER RANDOMIZED TRIAL OF HCV TREATMENT WITH PEGINTERFERON-ALFA 2A (Pegasys) AND RIBAVIRIN AFTER LIVER T
National AIDS Treatment Advocacy Project - Methods: 97 patients were included, with recurrent HCV and a minimum of stage 1 fibrosis (METAVIR scoring) on a liver biopsy obtained 1 to 5 years after LT. 75% of patients received tacrolimus and 25% cyclosporine. - ()